Search This Blog

Showing posts with label Grifols. Show all posts
Showing posts with label Grifols. Show all posts

Inauguration of the Grifols Chair for the Study of Cirrhosis

Grifols is sponsoring, along with Professor Vicente Arroyo, the Grifols Chair for the Study of Cirrhosis. Cirrhosis is a very common disease and represents the seventh leading cause of death in Europe, with an annual mortality rate in developed countries exceeding 200,000 persons. Professor Arroyo has been Director of the Department of Medicine at the University of Barcelona and of the Esther Kóplowitz Medical Reseach Center.

This private chair with an international reach was created to promote Reseach and Education of liver diseases, especially cirrhosis. In this sense, the academic nature of the Grifols Chair complements the clinical research work carried out since 2009 by the European Consortium for the Study of Chronic Liver Failure, which currently involves the participation of more than 80 university hospitals in 25 countries. The consortium is supported by the European Association for the Study of the Liver (EASL). The Grifols Chair will primarily focus on translational research and will collaborate closely with the Clinic Foundation for Biomedical Research (FCRB), an institution that contributed to the development of the consortium.

Both the Grifols Chair and the European Consortium for the Study of Chronic Liver Failure are supported by the European Foundation for the Study of Chronic Liver Failure (EF-CLIF), a recently created independent European medical foundation headquartered in Barcelona, Spain, which numbers Grifols, Professor Arroyo and the EASL among its patrons.

Grifols agrees long term loan with the European Investment Bank

Grifols one of the world's largest plasma product manufacturers and a pioneer in the research and development of therapeutic alternatives designed to contribute to both scientific and social development, has agreed a loan for 100 million euros with the European Investment Bank (EIB) following conclusion of financial and legal negotiations, including due diligence.
 
Grifols will use the EIB loan to support its investment in R&D, focusing primarily on the search for new indications for plasma proteins, including the treatment of Alzheimer's disease, vascular diseases, cardiovascular surgery and arterial thrombosis, amongst others.

Grifols is one of the first European companies to receive a loan from the new European Fund for Strategic Investments (EFSI), also known as the Juncker Plan. This is an initiative supported by the EIB and the European Commission, with the aim of reactivating investment in strategic projects throughout Europe, and its objectives include strengthening R&D in European companies.

Grifols hopes that its successful engagement with the EIB will encourage other Spanish companies to consider this source of funding for their projects.

Merger Project of companies of Grifols and Arrahona Optimus

With the aim of reducing management costs, the boards of directors of Grifols, S.A. and Arrahona Optimus, S.L. approved on 29 May 2015 a Merger Project, whereby in compliance with article 51 of Law 3/2009 of 3 April 2009 on structural modifications of commercial companies (Ley de Modificaciones Estructurales de las Sociedades Mercantiles), both management bodies approve to propose that Grifols, S.A. absorbs its wholly owned subsidiary Arrahona Optimus, S.L